In Reply In response to our study1 on TDM during infliximab induction, 3 letters address different aspects of the study design. Dr Papamichail and colleagues propose that subpopulations of patients with IBD may benefit from higher drug levels than recommended by the study algorithm. Our therapeutic range was based on data available when the study was being planned and after consultation with key opinion leaders on the international advisory board. The therapeutic range in NOR-DRUM Part A is consistent with prior studies and treatment guidelines.2-4 We cannot exclude additional benefit from higher infliximab levels on endoscopic remission in IBD subpopulations as suggested by Papamichail and colleagues based on cross-sectional postinduction data, but we await data from prospective studies.
Syversen SW, Bolstad N, Haavardsholm EA. Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory Diseases—Reply. JAMA. 2021;326(11):1069–1070. doi:10.1001/jama.2021.11480
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: